Dominari Holdings Inc. (DOMH) | Investment Case

1. Company Snapshot

1.a. Company Description

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics.The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia.It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.The company was formerly known as AIkido Pharma Inc.

and changed its name to Dominari Holdings Inc.in December 2022.Dominari Holdings Inc.

was founded in 1967 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on DOMH

The recent 3-month performance of Dominari Holdings Inc. was negatively impacted by the company's strategic shift towards Bitcoin mining, which led to a significant change in its business focus. The announcement of American Data Centers' transformation into American Bitcoin Corporation, a joint venture with Hut 8 Corp, marked a significant departure from Dominari's core business. Furthermore, the company's investment in industrial-scale Bitcoin mining and reserve development may have raised concerns about its long-term growth prospects. Additionally, the recent merger agreement between American Bitcoin and Gryphon Digital Mining may have created uncertainty among investors.

1.c. Company Highlights

Last Price	3.95
Change Percentage	3.13%
Open	3.85
Previous Close	3.83
Market Cap ( Millions)	63
Volume	181204
Year High	13.58
Year Low	0.83
M A 50	5.39
M A 200	5.42

FCF Yield	-11.47%
Dividend Yield	13.67%
ROE	116.21%
Debt / Equity	1.42%
Net Debt / EBIDTA	-3.29%
Price To Book	0.29
Price Earnings Ratio	0.55
Price To FCF	-8.72
Price To sales	0.63
EV / EBITDA	0.84

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Dominari 2025 Revenue Surges 703% in First Nine Months, Balance Sheet Strengthens Significantly

Nov -11

Source: prnewswire.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Dominari Holdings Inc. (NASDAQ: DOMH)

Oct -27

Source: prnewswire.com

Dominari Securities Raises Over $1.4 Billion Year-to-Date in Support of American Innovation and Entrepreneurship

Oct -16

Source: prnewswire.com

Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

Oct -09

Source: prnewswire.com

Dominari Holdings Announces Board Member Tim Ledwick to Assume Role of Interim Chief Financial Officer

Sep -23

Source: prnewswire.com

Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

Sep -10

Source: prnewswire.com

Dominari Holdings Applauds American Bitcoin's Nasdaq Debut; Highlights Strategic Stake

Sep -09

Source: prnewswire.com

Dominari Holdings Files $2 Billion Shelf to Support Strategic Expansion

Aug -28

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.50%)

6. Segments

Dominari Financial

Expected Growth: 12.5%

Dominari Financial's innovative financial solutions and investment opportunities will drive growth, fueled by increasing demand for digital banking, wealth management, and alternative investments among individuals and institutions.

7. Detailed Products

Cybersecurity Solutions

Comprehensive cybersecurity solutions to protect businesses from cyber threats

Cloud Services

Scalable and secure cloud infrastructure for businesses

Data Analytics

Advanced data analytics tools for business insights and decision-making

IT Consulting

Expert IT consulting services for businesses

Digital Transformation

Comprehensive digital transformation services for businesses

Managed Services

Proactive managed services for IT infrastructure and applications

8. Dominari Holdings Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Dominari Holdings Inc. is moderate due to the presence of alternative products and services in the market.

Bargaining Power Of Customers

The bargaining power of customers is high due to the concentration of buyers in the market, giving them significant negotiating power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is low due to the availability of multiple suppliers in the market, reducing their negotiating power.

Threat Of New Entrants

The threat of new entrants is moderate due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the market, leading to intense competition.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	6.12%
Debt Cost	3.95%
Equity Weight	93.88%
Equity Cost	8.57%
WACC	8.29%
Leverage	6.52%

11. Quality Control: Dominari Holdings Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Dominari Holdings

A-Score: 6.1/10

Value: 8.8

Growth: 6.2

Quality: 5.1

Yield: 6.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

Coherus BioSciences

A-Score: 4.9/10

Value: 8.2

Growth: 3.6

Quality: 6.5

Yield: 0.0

Momentum: 10.0

Volatility: 1.3

1-Year Total Return ->

Lineage Cell Therapeutics

A-Score: 4.5/10

Value: 6.2

Growth: 6.0

Quality: 4.6

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

Vanda Pharmaceuticals

A-Score: 4.2/10

Value: 9.0

Growth: 2.0

Quality: 4.4

Yield: 0.0

Momentum: 6.0

Volatility: 4.0

1-Year Total Return ->

Inhibrx

A-Score: 3.8/10

Value: 6.0

Growth: 3.3

Quality: 3.3

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

MediciNova

A-Score: 2.9/10

Value: 7.2

Growth: 4.6

Quality: 3.1

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

18.51%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.29%

Dominari Holdings Inc. - US0088753043

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on DOMH

1.c. Company Highlights

Fairly Valued

Stable Momentum

Average Yield

Cheaper

Weak Momentum

Medium Volatility

More Volatile

Higher Yield

Strong Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.50%)

6. Segments

Dominari Financial

Expected Growth: 12.5%

7. Detailed Products

Cybersecurity Solutions

Cloud Services

Data Analytics

IT Consulting

Digital Transformation

Managed Services

8. Dominari Holdings Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Dominari Holdings Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.95$

Current Price

3.95$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA